Pozen Inc. and its drug partner AstraZeneca have recently filed a patent infringement lawsuit at the New Jersey federal court for its drug Vimovo against Dr Reddy’s Laboratories. Vimovo is a NSAID (non-steroidal anti-inflammatory drug) used to treat various forms of arthritis and aids in decreasing the risk to develop gastric ulcers. Vimovo has been co- developed by both Pozen and AstraZeneca and covers in total seven patents. The litigation suit has been filed pertaining to the US patent no. 6,926,907.
Meanwhile Dr Reddy’s already notified both the drug manufacturers in the month of march this year, about its submission of an application regarding the generic version of Vimovo to FDA. It is noteworthy that FDA will give a final verdict on the marketing of Dr. Reddy’s generic drug after a final court decision is made in this regard and consequently Dr Reddy’s drug approval has been withheld for about 30 months. It is evident that one has to wait for the court’s final verdict in order to analyze the future outcomes in this case.
(Image by Dima V)
